Lodoxamide
Mast Cell Stabilizer — SENSORY ORGANS
Also known as: alomide, lodoxamide trometamol, lodoxamide tromethamine, U 42585E, U-42,585E
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Lodoxamide is an ofm drug in the Mast Cell Stabilizer class catalogued in DrugCentral. It was first approved by the FDA in 1993. DrugCentral lists 1 molecular target, including GPR35. Recorded indications include Vernal conjunctivitis, Vernal Keratitis and Vernal keratoconjunctivitis.
- Approval status: ofm (first approved 1993 by the FDA).
- Drug class: Mast Cell Stabilizer.
- Molecular targets: GPR35 (1 listed in DrugCentral).
- Indications: Vernal conjunctivitis, Vernal Keratitis and Vernal keratoconjunctivitis.
- ATC code: S01GX05 (Other antiallergics).
- Molecular formula: C11H6ClN3O6; molecular weight 311.64 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (3)
- Vernal conjunctivitis
- Vernal Keratitis
- Vernal keratoconjunctivitis
Off-label uses (3)
- Allergic conjunctivitis
- Allergic Keratoconjunctivitis
- Giant papillary conjunctivitis
Mechanism & targets
| Established pharmacologic class | Mast Cell Stabilizer |
|---|
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| G-protein coupled receptor 35 | GPR35 | agonist | EC50 8.79 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1993-09-23 | FDA | — | ALCON | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
S01GX05 | SENSORY ORGANS › OPHTHALMOLOGICALS › DECONGESTANTS AND ANTIALLERGICS › Other antiallergics |
Chemical structure
| Molecular formula | C11H6ClN3O6 |
|---|---|
| Molecular weight | 311.64 g/mol |
| CAS number | — |
| InChIKey | RVGLGHVJXCETIO-UHFFFAOYSA-N |
| PubChem CID | 44564 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Lodoxamide used for?
DrugCentral lists the following indications for Lodoxamide: Vernal conjunctivitis, Vernal Keratitis and Vernal keratoconjunctivitis.
How does Lodoxamide work?
Its molecular targets in DrugCentral include GPR35 (agonist).
When was Lodoxamide first approved?
Lodoxamide was first approved by the FDA in 1993.
What drug class does Lodoxamide belong to?
Lodoxamide is in the Mast Cell Stabilizer class.
What is the chemical formula of Lodoxamide?
Lodoxamide has the molecular formula C11H6ClN3O6 and a molecular weight of 311.64 g/mol.
Browse: all drugs starting with L · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 3325 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1201266 — compound record and bioactivity
- PubChem CID 44564 — chemical identifiers
- DrugBank DB06794 — drug record
- FDA UNII SPU695OD73 — substance identity
- DailyMed: FDA labels for Lodoxamide — current prescribing information (label search)
- UniProt Q9HC97 (GPR35) — target protein
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.